MDA’s commitment to research on myasthenia gravis began many years ago when little was known about the cause of MG and its mortality rate was high.
In the early 1970s, MDA-funded researchers helped establish the autoimmune nature of MG. They showed that people with the disease have a reduced number of ACh receptors, and that antibodies to the receptors can induce MG in laboratory animals.
These discoveries led swiftly to the lifesaving use of immunosuppressant drugs to treat the disease.